Literature DB >> 25131810

Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

Doralina do Amaral Rabello1, Antonio Roberto Lucena-Araujo2, Juliana Carvalho Rocha Alves-Silva1, Vinícius Burnett Aboud Souza da Eira1, Maria Catarina Cals de Vasconcellos3, Fábio Morato de Oliveira2, Eduardo Magalhaes Rego2, Felipe Saldanha-Araujo1, Fábio Pittella Silva4.   

Abstract

EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Cytogenetic; EZH2; Gene expression; Histone methyltransferase

Mesh：

Substances：

Year:  2014        PMID： 25131810     DOI： 10.1016/j.bcmd.2014.07.013

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN： 1079-9796            Impact factor:   3.039


  10 in total

1.  Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.

Authors:  Elisavet Chartomatsidou; Stavroula Ntoufa; Konstantia Kotta; Alessandra Rovida; Maria Anna Akritidou; Daniela Belloni; Elisabetta Ferrero; Theoni Trangas; Niki Stavroyianni; Achilles Anagnostopoulos; Richard Rosenquist; Paolo Ghia; Nikos Papakonstantinou; Kostas Stamatopoulos
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

3.  Efficacy of extracts of Celastrus orbiculatus in suppressing migration and invasion by inhibiting the EZH2/ROCK1 signaling pathway in human nasopharyngeal carcinoma.

Authors:  Xuanyi Wang; Yuxiang Huang; Yong Chen; Yong Ma; Fei Yang; Yayun Qian; Xiaojun Dai; Lede Tao; Haibo Wang; Renhua Guo; Yanqing Liu
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 4.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

5.  Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.

Authors:  Wilson Oliveira-Santos; Doralina Amaral Rabello; Antônio Roberto Lucena-Araujo; Fábio Morato de Oliveira; Eduardo Magalhaes Rego; Fábio Pittella Silva; Felipe Saldanha-Araujo
Journal:  Tumour Biol       Date:  2016-01-20

6.  Aberrant histone modification in CD19+ B cells of patients with chronic lymphocytic leukemia.

Authors:  Keshu Zhou; Qing Zhang; Yanyan Liu; Yuanyuan Xiong; Shengsheng Wu; Jingke Yang; Hu Zhou; Xinjian Liu; Xudong Wei; Yongping Song
Journal:  Onco Targets Ther       Date:  2017-02-23       Impact factor: 4.147

7.  EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia.

Authors:  Subazini Thankaswamy Kosalai; Mohammad Hamdy Abdelrazak Morsy; Nikos Papakonstantinou; Larry Mansouri; Niki Stavroyianni; Chandrasekhar Kanduri; Kostas Stamatopoulos; Richard Rosenquist; Meena Kanduri
Journal:  Epigenetics       Date:  2019-06-26       Impact factor: 4.528

8.  Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML.

Authors:  Julia M Kempf; Sabrina Weser; Michael D Bartoschek; Klaus H Metzeler; Binje Vick; Tobias Herold; Kerstin Völse; Raphael Mattes; Manuela Scholz; Lucas E Wange; Moreno Festini; Enes Ugur; Maike Roas; Oliver Weigert; Sebastian Bultmann; Heinrich Leonhardt; Gunnar Schotta; Wolfgang Hiddemann; Irmela Jeremias; Karsten Spiekermann
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

Review 9.  Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Authors:  Yu Nie; Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-06-27

Review 10.  EZH2 in normal hematopoiesis and hematological malignancies.

Authors:  Laurie Herviou; Giacomo Cavalli; Guillaume Cartron; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2016-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.